Onishi et al.2121 . Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94-100. http://dx.doi.org/10.1097/JTO.0b013e318074de34 http://dx.doi.org/10.1097/JTO.0b013e3180...
|
257 |
1-14 frações (30-84 Gy) |
Ambas |
84% (5 anos) BED ≥ 100 Gy |
≥ grau 3: 5,4% pulmonar; 1,0% esofágica; 1,2% dermatite |
Nagata et al.2222 . Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Stereotactic Body Radiation Therapy For T1N0M0 Non-small Cell Lung Cancer: First Report for Inoperable Population of a Phase II Trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys. 2012;84(Suppl):S46. http://dx.doi.org/10.1016/j.ijrobp.2012.07.330 http://dx.doi.org/10.1016/j.ijrobp.2012....
|
104 |
4 × 12 Gy |
Ambas |
69% sobrevida livre de progressão em 3 anos |
Grau 3: 9% dispneia; 7% pneumonite; 2% dor intercostal; 1% tosse Grau 4: 1% dispneia |
Baumann et al.2323 . Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45(7):787-95. http://dx.doi.org/10.1080/02841860600904862 http://dx.doi.org/10.1080/02841860600904...
|
57 |
3 × 15 Gy |
Periférica |
92% (3 anos) |
Grau 3: 28%; e grau 4: 1,7% |
Senthi et al.2424 . Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802-9. http://dx.doi.org/10.1016/S1470-2045(12)70242-5 http://dx.doi.org/10.1016/S1470-2045(12)...
|
676 |
3-8 frações (54-60 Gy) |
Ambas |
89% (5 anos) |
- |
Timmerman et al.1818 . Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833-9. http://dx.doi.org/10.1200/JCO.2006.07.5937 http://dx.doi.org/10.1200/JCO.2006.07.59...
|
70 |
3 × 20-22 Gy |
Ambas |
95% (2 anos) |
6% pneumonite; 3% de fratura de costela |
Brown et al.2525 . Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, et al. CyberKnife radiosurgery for stage I lung cancer: results at 36 months. Clin Lung Cancer. 2007;8(8):488-92. http://dx.doi.org/10.3816/CLC.2007.n.033 http://dx.doi.org/10.3816/CLC.2007.n.033...
|
59 |
1-5 frações (15,0-67,5 Gy) |
Ambas |
90% de sobrevida livre de doença |
Grau 3: 7% pneumonite |
Van der Voort et al.2626 . Van der Voort van Zyp NC, Prévost J-B, Hoogeman MS, Praag J, van der Holt B, Levendag PC, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91(3):296-300. http://dx.doi.org/10.1016/j.radonc.2009.02.011 http://dx.doi.org/10.1016/j.radonc.2009....
|
70 |
3 × 12-15 Gy |
Periférica |
96% (2 anos se 60 Gy) |
10% toxicidade tardia |